Associated Partners

Under IMI2, any legal entity can become an IMI Associated Partner. This page sets out the benefits of joining us as an Associated Partner, and explains how being an Associated Partner works in practice.

 

Who can become an Associated Partner?

The Associated Partner category was created with the goal of opening up our activities to a wider range of stakeholders. As such, examples of organisations that could become IMI Associated Partners include philanthropic organisations and charities that run their own health research programmes, as well as organisations working in sectors related to healthcare such as ICT, imaging, diagnostics, animal health, etc.

 

Benefits of being an Associated Partner

IMI Associated Partners join a vibrant, collaborative health innovation ecosystem, and enjoy benefits such as access to complementary skills, expertise, technology and data; the opportunity to share knowledge and risks in a non-competitive space; and the more efficient use of resources.

As contributors to the project, Associated Partners are involved in the definition of the project, and can participate as observers in IMI Governing Board meetings during discussions relating to the projects they are involved in.

 

IMI Associated Partners

So far, the following organisations have become IMI Associated Partners:

  • Accelerate Diagnostics contributes to the VALUE-Dx project on diagnostics for antimicrobial resistance.
  • Autism Speaks contributes to the AIMS-2-TRIALS project on autism. They were also involved in the IMI1 project EU-AIMS.
  • Autistica contributes to the AIMS-2-TRIALS project on autism.
  • BD Switzerland Sarl contributes to the VALUE-Dx project on diagnostics for antimicrobial resistance.
  • Bill and Melinda Gates Foundation contributes to the PERISCOPE project on pertussis (whooping cough) vaccines, ERA4TB, which seeks to speed up the development of new drug regimens needed to stop tuberculosis, and the CARE project on coronavirus therapeutics.
  • Bio-rad Laboratories contributes to the VALUE-Dx project on diagnostics for antimicrobial resistance.
  • Cepheid Europe contributes to the VHFMoDRAD project on diagnostics for Ebola and related diseases.
  • CEPI (Coalition for Epidemic Preparedness Innovations) contributes to the Ebola vaccine project EBOVAC3.
  • CHDI Foundation is contributing to IDEA-FAST, which aims to identify digital endpoints for fatigue and sleep disturbances in neurodegenerative and immune-mediated diseases.
  • Children's Tumor Foundation is contributing to EU-PEARL, which is designing integrated research platforms trials in order to revolutionise the way we do clinical trials by making them more efficient and patient friendly.
  • Datapharm contributes to Gravitate-Health.
  • Diamond Light Source contributes to EUbOPEN.
  • DZIF will contribute to UNITE4TB.
  • European Hematology Association (EHA) contributes to T2EVOLVE.
  • GHDDI (Global Health Drug Discovery Institute) contributes to the coronavirus therapeutics project CARE.
  • International Diabetes Federation contributes to the Hypo-RESOLVE project on diabetes.
  • Ion Beam Applications S.A. contributes to PROTECT, which is researching proton versus photon therapy for oesophageal cancer.
  • JDRF contributes to the diabetes projects INNODIA, INNODIA HARVEST, BEAT-DKD, Hypo-RESOLVE, Trials@Home, ImSAVAR, SOPHIA, and H2O.
  • KTH Royal Institute of Technology contributes to EUbOPEN. 
  • Leona M. and Harry B. Helmsley Charitable Trust contributes to the diabetes projects INNODIA, INNODIA HARVEST and Hypo-RESOLVE.
  • Link2Trials will contribute to Call 23 Topic 6 (patient adherence)
  • LMU Klinikum will contribute to UNITE4TB.
  • McGill University will contribute to IMI2 - Call 17, topic 2 (Open access chemogenomics library and chemical probes for the druggable genome).
  • Medicines for Malaria Venture (MMV) contributes to the ESCULAB project on a European Screening Centre as a unique library for attractive biology.
  • Obesity Action Coalition (OAC) contributes to SOPHIA. 
  • Ontario Institute of Cancer Research will contribute to IMI2 - Call 17, topic 2 (Open access chemogenomics library and chemical probes for the druggable genome).
  • Parkinson's UK contributes to the PD-MitoQUANT project on mitochondrial dysfunction in neurodegeneration); and the NEURONET coordination and support action for IMI projects in the neurodegeneration area. It will also contribute to IMI2 - Call 13, topic 14 (Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases); and IMI2 - Call 15, topic 6 (Digital endpoints in neurodegenerative and immune-mediated diseases).
  • Simons Foundation Autism Research Initiative (SFARI) contributes to the AIMS-2-TRIALS project on autism.
  • Software AG contributes to the RADAR-AD project on digital technologies and Alzheimer’s disease.
  • SpringWorks Therapeutics will contribute to IMI2 - Call 15, topic 1 (Integrated research platforms enabling patient-centric drug development).
  • T1D Exchange contributes to the Hypo-RESOLVE project on diabetes, and will contribute to IMI2 - Call 17, topic 1 (Optimising future obesity treatment).
  • TB Alliance will contribute to IMI2 - Call 15, topic 1 (Integrated research platforms enabling patient-centric drug development) and IMI2 - Call 15, topic 8 (Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic).
  • Trial Nation will contribute to IMI2 - Call 18, topic 2 (Health Outcomes Observatories – empower patients with tools to measure their outcomes in a standardised manner creating transparency of health outcomes).
  • University of Dundee will contribute to IMI2 - Call 15, topic 8 (Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic), and Call 21 on the coronavirus.
  • Varian Medical Systems Particle Therapy GmbH will contribute to IMI2 - Call 20, Topic 05 (Proton versus photon therapy for oesophageal cancer – a trimodality strategy).
  • Wellcome Trust contributes to the VALUE-Dx project on diagnostics for antimicrobial resistance.

 

Practical information

Details of how to become an Associated Partner can be found in this information guide.

In summary, organisations wishing to become Associated Partners must apply to the IMI Governing Board with a letter of endorsement (see templates below). In the letter, applicants should set out their acceptance of the IMI2 Statutes; commit to supporting the objectives of IMI2 in their specific area of research; and set out details of their contribution to IMI (e.g. in-kind/cash contributions, activities, duration, etc.). Organisations are requested to use the following templates to prepare their letters:

  • Template for organisations that want to apply to become Associated Partners - doc pdf
  • Template for existing Associated Partners that want to apply to expand the scope of their association, e.g. by contributing to a new Call topic or an existing project - doc pdf

To discuss the Associated Partner option in more detail, contact us